

Bladder Cancer Urothelial Carcinoma

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Trial Status
Completed

Trial Runs In
36 Countries

Trial Identifier
NCT02807636 2016-000250-35
WO30070

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02807636 2016-000250-35 WO30070
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
